drugset / Trial / NCT05182125
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
Phase 1
Completed
34 enrolled
HIV Vaccine Trials Network
Department of Health and Human Services · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 vaccines based on chimpanzee serotypes of adenovirus expressing clade C gp140 and a CH505TF gp120 protein boost in healthy, HIV- uninfected adult participants.
Timeline
- Start
- 2021-11-25
- Primary completion
- 2023-08-21
- Completion
- 2025-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdC6-HIVgp140 | Vaccine | 1e+10 unknown | Intramuscular |
| Subject | AdC6-HIVgp140 | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | AdC7-HIVgp140 | Vaccine | 1e+10 unknown | Intramuscular |
| Subject | AdC7-HIVgp140 | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | CH505TF gp120 | Protein / enzyme biologic | 400 ug | Intramuscular |
| Background | GLA-SE | Other / unclassified | 10 ug | Intramuscular |